Last $682.93 MXN
Change Today 0.00 / 0.00%
Volume 0.0
GSKN On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 4:08 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSKN) Snapshot

Open
$682.93
Previous Close
$682.93
Day High
$682.93
Day Low
$682.93
52 Week High
03/4/14 - $751.50
52 Week Low
05/9/13 - $609.35
Market Cap
1.7T
Average Volume 10 Days
3.9K
EPS TTM
--
Shares Outstanding
2.4B
EX-Date
02/19/14
P/E TM
--
Dividend
$3.05
Dividend Yield
4.64%
Current Stock Chart for GLAXOSMITHKLINE PLC-SPON ADR (GSKN)

glaxosmithkline plc-spon adr (GSKN) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc-spon adr (GSKN) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global R&D & Vaccines, Executive ...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc-spon adr (GSKN) Key Developments

GlaxoSmithKline plc and Genmab A/S Announces Approval of U.S. Food and Drug Administration for Supplemental Biologic License Application

GlaxoSmithKline plc and Genmab A/S announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra(R) (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate. The FDA approval of the first-line indication is based on results from a Phase III study (COMPLEMENT 1) which demonstrated statistically significant improvement in median progression-free survival (PFS) in patients who received the combination of ofatumumab and chlorambucil compared to patients who received chlorambucil alone. The results from COMPLEMENT 1, the randomised, open-label, parallel-arm, pivotal Phase III study evaluating the combination of ofatumumab and chlorambucil (N=221) versus chlorambucil alone (N=226) demonstrated statistically significant improvement in median PFS in patients randomised to ofatumumab and chlorambucil compared to patients randomised to chlorambucil alone (22.4 months versus 13.1 months, respectively) (HR=0.57 [95% CI, 0.45, 0.72] p<0.001). The majority of adverse reactions (ARs) were Grade 2 or lower in both treatment arms. The most common (>/=5% in the ofatumumab plus chlorambucil arm and also >/=2% more than in the chlorambucil monotherapy arm) non-infusion-related ARs (all grades) as reported by investigators within 60 days following the last treatment were neutropaenia (27% ofatumumab + chlorambucil, 18% chlorambucil), asthaenia (8%, 5%), headache (7%, 3%), leukopaenia (6%, 2%), herpes simplex (6%, 4%), lower respiratory tract infection (5%, 3%), arthralgia (5%, 3%), and upper abdominal pain (5%, 3%). Infusion reactions (IRs) were seen in 67% of patients in the ofatumumab plus chlorambucil arm. 10% of IRs were Grade 3 or greater. IRs that were Grade 3 or greater, serious or led to treatment interruption or discontinuation occurred most frequently with Cycle 1 and decreased with subsequent infusions.

GlaxoSmithKline plc Receives FDA for Approval Tanzeumtm (Albiglutide)

GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved TanzeumTM (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), is a biological product for the treatment of type 2 diabetes, administered once-weekly using an injector pen supplied with a 5mm 29-gauge thin-walled needle. Glucagon-like peptide-1 is an important incretin hormone that helps reduce blood glucose levels but, in people with type 2 diabetes, its production is often reduced or absent. The FDA approval of albiglutide is based on the results of GSK's comprehensive Phase III Harmony programme, consisting of eight trials and involving over 5,000 patients, over 2,000 of whom were treated with Tanzeum. The Harmony studies evaluated albiglutide against commonly-used classes of type 2 diabetes treatment, including insulin, metformin, glimepiride and pioglitazone, in patients at different stages of the disease, as well as those with renal impairment.

GSK Teams with MD Anderson to Develop Cancer Immunotherapies

GlaxoSmithKline and the MD Anderson Cancer Center in Houston will work together to identify new therapeutic approaches, evaluate patient outcomes in clinical testing and use that information to develop drugs that stimulate the body's own natural defenses against cancer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSKN:MM $682.93 MXN 0.00

GSKN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €94.15 EUR +1.21
Gilead Sciences Inc $70.00 USD +0.72
L'Oreal SA €121.35 EUR -0.75
Novo Nordisk A/S kr235.60 DKK +4.90
Sanofi €75.48 EUR +0.71
View Industry Companies
 

Industry Analysis

GSKN

Industry Average

Valuation GSKN Industry Range
Price/Earnings 14.3x
Price/Sales 2.9x
Price/Book 10.8x
Price/Cash Flow 14.1x
TEV/Sales 2.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.